Biogen: Phase 3 PHOENYCS GO Study With Dapirolizumab Pegol Meets Primary Endpoint
(RTTNews) - UCB (UCB) and Biogen (BIIB) announced positive topline results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol in people living with moderate-to-severe systemic lupus erythematosus. Dapirolizumab pegol, in addition to standard-of-care treatment, met the primary endpoint to demonstrate greater improvement of moderate-to-severe disease activity after 48 weeks versus placebo in addition to SOC. Also, clinical improvements were observed among key secondary endpoints measuring disease activity and flares.
Based on the successful outcome of the PHOENYCS GO study, the companies are initiating a second Phase 3 trial of dapirolizumab pegol in 2024, PHOENYCS FLY.
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.